Search
The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.
Memorial Sloan Kettering Cancer Center (MSK) today announced the largest single donation in its nearly 150-year history, a $400 million gift from Kenneth C. Griffin, Founder and Chief Executive Officer of Citadel and Founder of Griffin Catalyst, and David Geffen, Founder of The David Geffen Foundation. It will serve as the cornerstone of MSK’s foundation for the future and will be instrumental in extending the power and potential of cancer care and treatment to people across New York and around the world as MSK continues to advance cutting-edge research and new cancer treatments.
Memorial Sloan Kettering Cancer Center will recognize three young investigators for their exceptional bodies of innovative work that has helped to advance the field of cancer research. The researchers will receive the Paul Marks Prize for Cancer Research, an award presented biennially by Memorial Sloan Kettering to honor promising scientists under the age of 46.
Uniting MSK’s research and clinical expertise with AWS’s advanced cloud technologies is a bold step towards addressing one of the world’s most pressing health challenges.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
The May 4 session of “MSK Science Spotlight” will feature series host, Andrea Schietinger, PhD, Assistant Member, Immunology Program, SKI, presenting her own research, “Decoding T Cell Dysfunction in Tumors.” Dr. Schietinger, a former winner of the prestigious National Institutes of Health Director’s New Innovator Award, has served as host for past sessions of the online seminar series for the scientific community.
Researchers shed light on how aberrant cell division can cause the kind of mutations often found in cancer cells.
An MSK research team aims to find new ways to stop the most common and deadly form of ovarian cancer — high-grade serous ovarian cancer — from recurring with the help of a method they developed for tracking the evolution of treatment resistant cells in ovarian cancer using blood tests.
David Solit, MD, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, is the featured speaker for the June 3 episode of “MSK Science Spotlight.”
Learn about the questions to ask a lung cancer doctor after being diagnosed, from an MSK specialist who has successfully treated many people for lung cancer.